Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2009-12-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate
NCT01821989
Lactoferrin for Prevention of Sepsis in Infants
NCT01525316
Pilot Study: Lactoferrin for Prevention of Neonatal Sepsis
NCT01264536
Clinical Trial for Valuation of the Effectiveness of Lactoferrine in the Prevention of Sepsis in New Premature Born. Bimonitorization of the Antinflammatory Mechanisms, Antioxidants and the Intestinal Microbiote.
NCT03472170
Early Versus Late Lactoferrin in Prevention of Neonatal Sepsis
NCT02959229
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
In born VLBW infants with parental consent form signed will be given oral saline daily as placebo until discharge
Lactoferrin (bovine origin)
Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
Lactoferrin
In born VLBW infants with parental consent form signed will be given oral bovine lactoferrin daily until discharge
Lactoferrin (bovine origin)
Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lactoferrin (bovine origin)
Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestational age \< 32 weeks
* Birth weight \< 1500 g
* Parental consent
Exclusion Criteria
* Severe perinatal asphyxia
15 Minutes
1 Day
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ankara University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ilke Mungan Akin
Neonatologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Saadet Arsan, Prof
Role: STUDY_CHAIR
Anlara University Chief of Neonatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ankara University School of Medicine Department of Pediatrics, NICU
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Lactoferrin
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.